Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
antibody-drug conjugates
Biotech
Vertex pays ImmunoGen $15M to pair ADCs with CRISPR therapy
Vertex is paying ImmunoGen $15 million upfront to explore the use of ADCs with its near-approval CRISPR/Cas9 therapy exa-cel.
Nick Paul Taylor
Mar 1, 2023 9:09am
AstraZeneca doubles down on cancer target, paying $63M for ADC
Feb 23, 2023 4:41am
AstraZeneca-Daiichi lay down phase 1 breast cancer data for ADC
Dec 9, 2022 9:50am
NextCure, LegoChem join big-league rivals in ADC race
Nov 16, 2022 9:40am
Exelixis goes 3 in 3 with $30M for 3 Catalent programs
Nov 3, 2022 1:20pm
ESMO: Daiichi dazzles in lung cancer to dial up hopes for ADC
Sep 12, 2022 8:30am
